UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000007350
Receipt number R000008658
Scientific Title Effects on Blood Pressure, Cardio-Renal Function and Vascular Endothelial Function by HyperUricemia Treatment Study
Date of disclosure of the study information 2012/02/21
Last modified on 2012/02/21 19:53:29

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Effects on Blood Pressure, Cardio-Renal Function and Vascular Endothelial Function by HyperUricemia Treatment Study

Acronym

Effects on Blood Pressure, Cardio-Renal Function and Vascular Endothelial Function by HyperUricemia Treatment Study
(HUT Study)

Scientific Title

Effects on Blood Pressure, Cardio-Renal Function and Vascular Endothelial Function by HyperUricemia Treatment Study

Scientific Title:Acronym

Effects on Blood Pressure, Cardio-Renal Function and Vascular Endothelial Function by HyperUricemia Treatment Study
(HUT Study)

Region

Japan


Condition

Condition

Hyperuricemia

Classification by specialty

Medicine in general Cardiology Nephrology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the effects of hyperuricemia treatment; febuxostat, inhibitor of xanthine oxidase on blood pressure, cardio-renal function, vascular endothelial function, arteriosclerosis, uric acid, sugar and lipid metabolism by multicenter prospective trial.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

1. Vascular endothelial function(flow mediated dilatation, pulse wave velocity, carotid intima-media thickness)
2. Cardio-renal function(NT-pro BNP, estimated GFR, cardiac echography)
3. Blood pressure

Key secondary outcomes

1. The change of serum uric acid
2. Ankle brachial index
3. Cytokine: 9-OhdG, MDA-LDL, CRP, IL-6, AGE, RAGE, NOx, Angintensin2, ADMA, IGF-alpha
4. Blood sugar, insulin, HbA1c, HOMA-beta
5. LDL-cholesterol, HDL-cholesterol, trigliceride
6. Blood test: BUN, creatinine, AST, ALT, LDH, ALP, sodium, potacium, cloride, homocystein
7. Urine test: uric acid, creatinin, sodium, potacium, cloride


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -but assessor(s) are blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Febuxostat 10mg once a day for 2 weeks.
Febuxostat 20mg once a day after 2 weeks

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

hyperuricemia patients eligible for all the points of the following:
(1) Japanese male or female, 20 years old or above at the time of informed consent
(2) Serum uric acid > 8.0mg/dL
(3) Not treated with uric acid lowering agent within 3 month before the timing of eligibility judgement
(4) Patients enable to measure vascular endotherial function
(5) Patinets from which informed consent is obtained

Key exclusion criteria

(1)Patients having anti-hyperuricemia medication
(2)Patients with hypersensitivity to febuxostat
(3)HbA1c is 8% and over
(4)Patients with medication including NO donor
(5)Hepatic impairment patients (AST, ALT is more than double of standard values)
(6)Pregnant female, lactation femal, hoping gestation
(7)Patients with corticosteroid 10mg/day and over
(8)Treated patients with mercaptopurine or azathioprine
(9)Patints having malignancy
(10)Patients whom study physicians consider as not eligible.

Target sample size

50


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Niwa Koichiro

Organization

St.Lukes International Hospital

Division name

Department of Cardiology

Zip code


Address

9-1 Akashi-cho, Tyuuou-ku, Tokyo

TEL

03-3541-5151

Email



Public contact

Name of contact person

1st name
Middle name
Last name Kuwabara Masanari

Organization

St. Lukes International Hospital

Division name

Department of Cardiology

Zip code


Address

9-1 Akashi-cho, Tyuuou-ku, Tokyo

TEL

03-3541-5151

Homepage URL


Email

kuwamasa728@ybb.ne.jp


Sponsor or person

Institute

St. Lukes International Hospital

Institute

Department

Personal name



Funding Source

Organization

Advanced Clinical Research Organization

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

聖路加国際病院


Other administrative information

Date of disclosure of the study information

2012 Year 02 Month 21 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2011 Year 09 Month 13 Day

Date of IRB


Anticipated trial start date

2011 Year 10 Month 01 Day

Last follow-up date

2013 Year 03 Month 01 Day

Date of closure to data entry

2013 Year 03 Month 01 Day

Date trial data considered complete

2013 Year 03 Month 01 Day

Date analysis concluded

2013 Year 06 Month 01 Day


Other

Other related information



Management information

Registered date

2012 Year 02 Month 21 Day

Last modified on

2012 Year 02 Month 21 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000008658


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name